Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Dr. Hans Merks

Principal Investigator
Dr. Hans Merks
Dr. Hans Merks
The focus of the Merks group is to answer key clinical questions in pediatric sarcoma treatment with the aim to improve cure and quality of life. As Chair of the European pediatric Soft tissue sarcoma Study Group (EpSSG) and Vice-Chair of the Executive Board of the EuroEwing Consortium (EEC) Merks’ aim is to coordinate, design and implement international prospective clinical trials, including translational research, focused on sarcoma across the pediatric and young adult age range. Research in pediatric sarcoma pre-eminently is a multidisciplinary collaboration including a diversity of basic, translational and clinical research partners.
  • Correction to: Imaging in rhabdomyosarcoma: a patient journey (Pediatric Radiology, (2023), 53, 4, (788-812), 10.1007/s00247-023-05596-8)

    • jan. 2023
    • Isabelle S A, de Vries, et al
    • Pediatric Radiology
  • Single-cell transcriptomics reveals immune suppression and cell states predictive of patient outcomes in rhabdomyosarcoma

    • jan. 2023
    • Jeff, DeMartino, et al
    • Nature communications
  • Essential medicines for childhood cancer in Europe

    • dec. 2022
    • , et al
    • The Lancet Oncology
  • Rhabdomyosarcoma with unknown primary tumor site

    • dec. 2022
    • Maria Carmen, Affinita, et al
    • Pediatric Blood and Cancer
  • Patients with completely resected nongenitourinary low-risk embryonal rhabdomyosarcoma are candidates for reduced duration low-intensity chemotherapy

    • dec. 2022
    • Gianni, Bisogno, et al
    • Cancer
View all publications